Literature DB >> 15487967

Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

Christine Y Lu, Kenneth M Williams, Lyn March, James V Bertouch, Richard O Day.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15487967

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  4 in total

1.  Recent developments in targeting access to high cost medicines in Australia.

Authors:  Christine Y Lu; Jan Ritchie; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2005-11-23

2.  Patient access schemes in Asia-pacific markets: current experience and future potential.

Authors:  Christine Y Lu; Caitlin Lupton; Shana Rakowsky; Zaheer-Ud-Din Babar; Dennis Ross-Degnan; Anita K Wagner
Journal:  J Pharm Policy Pract       Date:  2015-02-16

3.  The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia.

Authors:  Christine Y Lu; Jan Ritchie; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2007-12-20

4.  Access to high cost medicines in Australia: ethical perspectives.

Authors:  Christine Y Lu; Paul Macneill; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2008-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.